menu

Loading...

NRSN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

0.850

Open

0.850

VWAP

0.85

Vol

4.51K

Mkt Cap

28.39M

Low

0.850

Amount

3.84K

EV/EBITDA(TTM)

--

Total Shares

33.40M

EV

27.72M

EV/OCF(TTM)

--

P/S(TTM)

--

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Show More

Events Timeline

(ET)

2026-02-18

09:10:00

NeuroSense Releases Long-Term Survival Data from ALS Clinical Trial

2026-02-09 (ET)

2026-02-09

09:30:00

NeuroSense Secures Australian Patent for PrimeC

2026-01-29 (ET)

2026-01-29

17:30:00

NeuroSense Files $150M Mixed Securities Shelf

2025-12-22 (ET)

2025-12-22

09:30:00

NeuroSense Completes Safety Analysis of PrimeC in Alzheimer's Phase 2 Study with No Serious Adverse Events

2025-11-24 (ET)

2025-11-24

10:01:21

NeuroSense Announces FDA Approval to Begin Phase 3 Trial of PrimeC for ALS

2025-08-20 (ET)

2025-08-20

09:48:47

NeuroSense reveals that 20% of ALS patients in Phase 2a study continue treatment with PrimeC

2025-01-06 (ET)

2025-01-06

08:06:45

NeuroSense regains Nasdaq compliance

2024-12-23 (ET)

2024-12-23

08:02:25

NeuroSense enters binding term sheet to advance PrimeC for ALS

News

PRnewswire

02-18PRnewswire

NeuroSense Releases New ALS Treatment Data

PRnewswire

02-09PRnewswire

NeuroSense Secures Australian Patent, Strengthening Global IP for PrimeC

seekingalpha

01-21seekingalpha

NeuroSense Therapeutics Secures U.S. Patent for PrimeC Alzheimer’s Therapy Valid Through 2043

PRnewswire

01-21PRnewswire

NeuroSense Secures U.S. Patent for PrimeC Combination in Alzheimer's Treatment

PRnewswire

01-08PRnewswire

NeuroSense Appoints Alzheimer's Expert Prof. Arnold to Advance PrimeC Development

NASDAQ.COM

2025-12-26NASDAQ.COM

Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway

2 Analyst Rating

Wall Street analysts forecast NRSN stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

7.50

Averages

8.25

High

9.00

Current: 0.000

Low

7.50

Averages

8.25

High

9.00

Noble Capital

Robert LeBoyer

initiated

$9

AI Analysis

2025-10-14

Reason

Noble Capital

Robert LeBoyer

Price Target

$9

AI Analysis

2025-10-14

initiated

Reason

Noble Capital analyst Robert LeBoyer initiated coverage of NeuroSense with an Outperform rating and $9 price target. Lead product PrimeC has completed two Phase 2 trials for Amyotrophic Lateral Sclerosis and has a Phase 3 trial planned for early 2026, notes the analyst, who adds that initial results from a Phase 2 study in Alzheimer's disease showed "promising data."

D. Boral Capital

Jason Kolbert

Buy

initiated

$14

2025-05-12

Reason

D. Boral Capital

Jason Kolbert

Price Target

$14

2025-05-12

initiated

Buy

Reason

D. Boral Capital analyst Jason Kolbert initiated coverage of NeuroSense with a Buy rating and $14 price target. NeuroSense is a clinical-stage biotechnology company advancing a novel combination therapy platform targeting neurodegenerative diseases, with its lead candidate, PrimeC, in development for amyotrophic lateral sclerosis, the analyst tells investors in a research note. The firm says its bullish stance is supported by a "differentiated mechanistic approach, encouraging early clinical signals, and a disciplined strategy toward regulatory and commercial milestones."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NRSN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Neurosense Therapeutics Ltd (NRSN.O) is -2.54, compared to its 5-year average forward P/E of -2.10. For a more detailed relative valuation and DCF analysis to assess Neurosense Therapeutics Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.10

Current PE

-2.54

Overvalued PE

-1.10

Undervalued PE

-3.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

11.88

Current PS

54.71

Overvalued PS

46.16

Undervalued PS

-22.41

Financials

AI Analysis

Annual

Quarterly

Whales Holding NRSN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Neurosense Therapeutics Ltd (NRSN) stock price today?

The current price of NRSN is 0.85 USD — it has increased 0

What is Neurosense Therapeutics Ltd (NRSN)'s business?

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

What is the price predicton of NRSN Stock?

Wall Street analysts forecast NRSN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRSN is8.25 USD with a low forecast of 7.50 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Neurosense Therapeutics Ltd (NRSN)'s revenue for the last quarter?

Neurosense Therapeutics Ltd revenue for the last quarter amounts to 0.00 USD, decreased -100.00

What is Neurosense Therapeutics Ltd (NRSN)'s earnings per share (EPS) for the last quarter?

Neurosense Therapeutics Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Neurosense Therapeutics Ltd (NRSN). have?

Neurosense Therapeutics Ltd (NRSN) has 15 emplpoyees as of March 04 2026.

What is Neurosense Therapeutics Ltd (NRSN) market cap?

Today NRSN has the market capitalization of 28.39M USD.